Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
To evaluate the long-term efficacy of sodium ipodate (IPO) in the treatment of hyperthyroid Graves' disease, we studied 12 consecutive patients with Graves' hyperthyroidism treated only with 500 mg IPO po daily for several weeks to 22 months. Serum thyroid hormone concentrations markedly decreased and serum free T3 values normalized in all patients within 7 days of therapy. Five patients (42%, Group 1) were euthyroid after 6 weeks of IPO treatment and remained so until IPO was discontinued after 22 months. Recurrence of hyperthyroidism after drug withdrawal occurred in only one of these Group 1 patients, who was promptly responsive to a second course of IPO. In contrast, seven of 12 patients (58%, Group 2) relapsed with recurrent hyperthyroidism between 14 and 42 days of IPO therapy. After IPO was withdrawn, these Group 2 patients were treated with methimazole (20-30 mg/day, initial dose), but the therapeutic response was poor and delayed. Two patients were still hyperthyroid after 6 months of methimazole treatment. Elevated serum FT3 concentrations were observed in the Group 2 patients at 21 days following the early normalization of serum FT3 concentrations. No changes in serum thyroglobulin and thyroid microsomal and TSH-receptor autoantibody titers were observed in either groups during IPO therapy. In conclusion, the results of the present study demonstrate that IPO rapidly restores euthyroidism, but its prolonged administration is associated with a high rate of relapse of hyperthyroidism and a poor response to subsequent methimazole treatment and that long-term IPO administration does not affect humoral markers of thyroid autoimmunity.
Cattedra di Endocrinologia, Università di Cagliari, Italy.
E
E
Martino
S
S
Balzano
L
L
Bartalena
A
A
Loviselli
V
V
Sica
L
L
Petrini
L
L
Grasso
M
M
Piga
L E
LE
Braverman
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001323:Autoantibodies / Q000097:blood; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating; D007487:Ipodate / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D012008:Recurrence; D013954:Thyroglobulin / Q000097:blood; D013961:Thyroid Gland / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D001323:Autoantibodies; D018828:Immunoglobulins, Thyroid-Stimulating; C056626:thyroid microsomal antibodies; D014284:Triiodothyronine; D008713:Methimazole; D013972:Thyrotropin; D013954:Thyroglobulin; D007487:Ipodate; D013974:Thyroxine